Advertisement
Advertisement
CRDF
Cardiff Oncology, Inc. Common Stock
0.96
USDSponsored
-0.03
-3.32%
Aug 10, 10:32 UTC -4
Open
CRDF Earnings Reports
Positive Surprise Ratio
CRDF beat 24 of 41 last estimates.
59%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$76.50K
/-$0.16
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
-36.25%
/-5.88%
Cardiff Oncology, Inc. Common Stock earnings per share and revenue
On Jul 30, 2026, CRDF reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of -0.16 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 72.12 thousand, with a --% difference. The market reacted with a +0.52% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.16 USD, with revenue projected to reach 76.50 thousand USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Intellia Therapeutics, Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.81
Actual
-$0.80
Surprise
+1.86%
SAB Biotherapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.29
Actual
-$0.28
Surprise
+5.15%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
MAIA Biotechnology, Inc.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.13
Surprise
-15.86%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Apogee Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$1.09
Actual
-$1.13
Surprise
-4.39%
Immunovant, Inc. Common Stock
Report Date
Aug 06, 2026 For Q1 27
Estimate
-$0.62
Actual
-$0.75
Surprise
-19.48%
Scholar Rock Holding Corporation Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.85
Actual
-$0.84
Surprise
+2.01%
Ligand Pharmaceuticals Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.90
Actual
$2.37
Surprise
+24.56%
FAQ
What were Cardiff Oncology, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Cardiff Oncology, Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Cardiff Oncology, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 0.52%, changed from $0.85 before the earnings release to $0.86 the day after.
When is Cardiff Oncology, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Cardiff Oncology, Inc. Common Stock's next earnings report?
Based on --
analysts, Cardiff Oncology, Inc. Common Stock is expected to report EPS of -$0.16 and revenue of $76.50K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement